ArticleGut2005
Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
Article in Gut, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 59 citations in OpenAlex.
- Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.Medical oncology (Northwood, London, England) · 2013Trial
- The Fas-FasL system: from apoptosis regulator to therapeutic target in autoimmunity, cancer, and transplantation.Immunologic research · 2026Review
- Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma GrowthACS nano · 2022Article
- Role of metalloproteases in the CD95 signaling pathways.Frontiers in immunology · 2022Review
- Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Review
- SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.Cancer letters · 2020Article
- The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2019Review
- SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.Cancer immunology research · 2019Article
- In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells.Scientific reports · 2019Article
- Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.Molecular cancer research : MCR · 2019Article
- CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.International journal of cancer · 2018Article
- Anaphase-Promoting Complex 7 is a Prognostic Factor in Human Colorectal Cancer.Annals of coloproctology · 2017Article
- Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells.Oncology letters · 2017Article
- Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients.Oncology letters · 2016Article
- H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- The role of CD95 and CD95 ligand in cancer.Cell death and differentiation · 2015Review
- Article
- Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines.Apoptosis : an international journal on programmed cell death · 2014Article
- DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence.Apoptosis : an international journal on programmed cell death · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLoss of CD95 expression in tumour cells occurs frequently in colon carcinoma and may be associated with disease progression. On the other hand, neo-expression of CD95L in tumour cells may contribute to immune evasion.
aimsWe aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in colon carcinomas. PATIENTS AND
methodsCD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer) stage II/III colon carcinomas and correlated with disease free survival.
resultsCD95 expression in tumour cells was observed in only 30 carcinomas (23.4%) whereas the others had at least a minor subpopulation of CD95 negative cells. Loss of CD95 in tumour cells was related to adverse prognosis in uni- and multivariate analysis (p = 0.046 and p = 0.036, respectively). Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in colon carcinomas. CD95L+TIL were present in 83% of cases whereas CD95L was found in tumour cells in only 12% of cases. Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC stage II (p = 0.05) but not in those with stage III.
conclusionsLoss of CD95 in tumour cells may be an independent prognostic factor in colon carcinomas. The CD95L counterattack is not a relevant feature in colon carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.